Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer
Study evaluated alternate-day administration of S-1 as second-line chemotherapy for unresectable pancreatic cancer in a multicenter, randomized, phase II study. Median OS was 4.5 months for the daily group and 4.4 months in the alternate- day group. Grade 3 or higher adverse events occurred with significantly higher incidence in the Daily group.
